Biochemistry and autoimmune response to the 2-oxoacid dehydrogenase complexes in primary biliary cirrhosis.
Pyruvate dehydrogenase complex (PDC), 2-oxo-glutarate dehydrogenase complex (OGDC), and the branched-chain 2-oxoacid dehydrogenase complex (BCOADC) constitute the 2-oxoacid dehydrogenase family of multienzyme complexes. These complexes, which are larger than ribosomes and which consist of multiple copies of E1, E2, and E3 subunits together with regulatory kinases and phosphatases and, in the case of PDC, an E3-binding protein (protein X), each play an important role in oxidative metabolism in mitochondria. Primary biliary cirrhosis (PBC) is associated with a high incidence of autoantibodies directed at mitochondrial autoantigens (the antimito-chondrial antibodies), identified as the E2 components of PDC, OGDC, and BCOADC, together with protein X and the E1 alpha and E1 beta subunits of PDC. The dominant B-cell autoepitope in PBC has been identified as the inner lipoic acid binding domain of PDC-E2, with the lipoic acid co-factor, which plays a critical role in E2 enzymatic activity, playing a role in autoantibody binding to antigen. Autoreactive CD4+ T cells specific for human PDC-E2 are also present in both the peripheral blood and liver mononuclear cell infiltrates of PBC patients. The mechanism of break-down of B-cell and T-cell self-tolerance to these ubiquitous mitochondrial antigens in such an organ-specific manner remains unclear. The apparent importance of autoreactive responses to these self-antigens does, however, raise the possibility that antigen-specific immunotherapy may offer a novel route to therapy in PBC.
Bassendine
M F
MF
Department of Medicine, Medical School, University of Newcastle, Newcastle-upon-Tyne, U.K.
Jones
D E
DE
Yeaman
S J
SJ
D042942:3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide); D000937:Antigen-Antibody Reactions; D001323:Autoantibodies / Q000276:immunology; D001324:Autoantigens / Q000276:immunology; D001327:Autoimmune Diseases / Q000201:enzymology* / Q000276:immunology / Q000628:therapy; D001402:B-Lymphocytes / Q000201:enzymology / Q000276:immunology; D001669:Biochemical Phenomena; D001671:Biochemistry; D001769:Blood; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D000939:Epitopes; D006801:Humans; D007167:Immunotherapy; D007655:Ketoglutarate Dehydrogenase Complex / Q000276:immunology; D007658:Ketone Oxidoreductases / Q000276:immunology*; D008099:Liver / Q000276:immunology / Q000473:pathology; D008105:Liver Cirrhosis, Biliary / Q000201:enzymology* / Q000276:immunology / Q000628:therapy; D008930:Mitochondria, Liver / Q000201:enzymology / Q000276:immunology; D009097:Multienzyme Complexes / Q000276:immunology*; D010084:Oxidation-Reduction; D010455:Peptides; D011768:Pyruvate Dehydrogenase Complex / Q000276:immunology; D017634:Self Tolerance / Q000276:immunology; D008063:Thioctic Acid / Q000378:metabolism
D001323:Autoantibodies; D001324:Autoantigens; D000939:Epitopes; D009097:Multienzyme Complexes; C045867:PDHX protein, human; D010455:Peptides; D011768:Pyruvate Dehydrogenase Complex; D008063:Thioctic Acid; D007658:Ketone Oxidoreductases; D007655:Ketoglutarate Dehydrogenase Complex; D042942:3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide)